Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Having founded in 1994, the company conducted various preclinical development programs, including the BEXXAR® therapy and the MELACINE® vaccine. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are powered by Corixa™ technology with the goal of making its potential products available to patients around the world. Corixa was acquired by GlaxoSmithKline on 12 July 2005, and GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines. The company ceased operations in March 2006.

STR Biotech Co. Ltd. engages in the development of drugs and immune materials. The company was founded on February 22, 2002 and is headquartered in Chuncheon, South Korea.

Faron Pharmaceuticals Oy operates as a clinical stage biopharmaceutical company. It develops novel treatments for medical conditions with significant unmet needs caused by dysfunction of immune system. The firm currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Its Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. The company was founded by Juho Markku Jalkanen, Sirpa Tuulikki Jalkanen, Matti Esa Manner, Juha Peltola, Marko Salmi, Katriina Peltola and Maija-Leena Hollmen in 2003 and is headquartered in Turku, Finland.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Nuvo Research AG, part of Nuvo Pharmaceuticals, Inc., is a Swiss company located in Fribourg that manufactures pharmaceuticals.

Taizhou Maibotaike Pharmaceutical Co., Ltd., established on 2015-02-04, Business scope includes biological products,Diagnostic reagents,Chemical Biological Reagent,Drug research and development,technical consulting,Technology Transfer and Technical Services(human stem cells,Except for the development and application of genetic diagnosis and treatment technology),Import, export and wholesale business involving the above goods and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:pharmaceutical production(Steamed Chinese Herbal Pieces,saute,broil,The application of calcining and other processing technologies and the production of secret prescription products of Chinese patent medicines)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Sami-Sabinsa Group Ltd. manufactures & markets nutraceuticals, herbal extracts, chemicals and active pharmaceutical ingredients. It also offers probiotics, enzymes, spice extracts, minerals and oils. The company was founded in 1991 by Muhammed Majeed and is headquartered in Bangalore, India.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Provides research and consulting services for small and medium-sized companies

ModiQuest specializes in the generation of monoclonal antibodies against difficult target antigens for R&D, diagnostic and therapeutic applications. Using its proprietary ModiFuse™ (hybridoma electrofusion), ModiSelect™ (B-cell selection) and ModiPhage™ (phage display) technologies, ModiQuest can generate very large panels of monoclonal antibodies from various backgrounds such as mouse, rat, rabbit, chicken, llama and human, as well as transgenic animals harboring the human immunoglobulin (antibody) gene repertoire, against virtually any target. Besides antibody lead generation, ModiQuest also provides extensive antibody development and optimization procedures, such as affinity maturation, humanization, stable cell line generation and antibody production in transient and stable mammalian cell systems.

Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.

Denka Corp., part of Denka Co., Ltd., is an American company located in New York, NY. The firm manufactures and distributes chemical products.

ImmuneOnco Biopharma, founded in June of 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an early stage biopharmaceutical company dedicated to the development and commercialization of novel cancer immunotherapy products designed to reverse cancer cell-induced immune inhibition and to actively eradicate cancer cells.

Specializes in biopharmaceutical products with focus in immunotherapy for the treatment of cancer

Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.

Immunex Corporation develops, manufactures, and markets therapeutic products for the treatment of cancer, infectious diseases, and autoimmune disorders. It offers products, such as Enbrel that is used in the treatment of rheumatoid arthritis; Novantrone, which is used to treat acute nonlymphocytic leukemia and pain associated with prostate cancer; and Leukine for use in bone marrow transplant patients. The company has franchise operations. It has a strategic alliance with American Home Products. The company was founded in 1981 and is based in Seattle, Washington. As of July 15, 2002, Immunex Corporation was acquired by Amgen, Inc.

LFB Biotechnologies SASU provides plasma-derived medicinal products. The firm undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The company was founded on September 21, 2006 and is headquartered in Courtaboeuf, France.